Biologic agents used in the treatment of psoriasis include the anti-tumor necrosis factor (TNF) agents Adalimumab, Etanercept, Infliximab, and Certolizumab pegol; the anti-interleukin (IL)-12/IL-23 antibody Ustekinumab; the anti-IL-17 antibodies Secukinumab and Ixekizumab; the anti-IL-17 receptor antibody Brodalumab; and the anti-IL-23 antibodies Guselkumab, Tildrakizumab, and Risankizumab [15]. The gene discussed is TNF; the disease is psoriasis.